Merck & Co (MRK) Fair Value & Analysis
Healthcare · US · Market cap $297B
Merck & Co
MRK · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Share price +12.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $70.28 – $119.60 · fair‑value band $72.16 – $187.51 · the $119.60 price screens below the $127.57 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Merck & Co (MRK) currently trades at $119.60, while our model-based Fair Value estimate is $127.57 — implying the stock looks roughly 6.7% undervalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Merck & Co generated revenue of $65.8B at a net margin of 13.6%. Revenue grew 4.9% year over year. It earns a return on equity of 18.9%. Net debt stands at $36.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Merck & Co reported revenue of $64.9B in FY2025 versus $48.7B in FY2021, a compound +7.5%/yr. Reported net income was $18.3B in FY2025, compounding +8.8%/yr from FY2021.
Is MRK fairly valued? → Check now
Recent news
- MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
- Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
- Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
- Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,107 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 2,944 MXN | -29% |
| Johnson & Johnson, JNJB34 | R$82.15 | R$58.27 | -29% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Merck & Co (MRK) undervalued?
What is the fair value of MRK?
What is the quality score of MRK?
What is the revenue of Merck & Co (MRK)?
What is the net profit margin of MRK?
Does Merck & Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.